Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Acetate

FDA-approved product (injectable, injection), marketed as Carmol Hc, Cortef Acetate, Cortifoam and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Inflammation
  • Pruritus
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Hydrocortisone Acetate reaches ≥40% AI-predicted activity against MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia

    NCT06488794 · start 2027-01-01

    Registered record
    Registry ID
    NCT06488794
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    colistimethate sodium; 0.9% Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01-01
    Completion
    2028-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    Interventioncolistimethate sodium; 0.9% Saline
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Phenotypic and Genotypic Detection of Colistin Resistance

    NCT07487116 · start 2026-08

    Registered record
    Registry ID
    NCT07487116
    Conditions
    Patients With Multi Drug Resistant Gram-negative Bacteria; Colistin Resistance in Bacteria
    Interventions
    disk elution test
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2029-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatients With Multi Drug Resistant Gram-negative Bacteria; Colistin Resistance in Bacteria
    Interventiondisk elution test
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex

    NCT06087536 · start 2026-05-14

    Registered record
    Registry ID
    NCT06087536
    Conditions
    Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia
    Interventions
    OMN6; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-14
    Completion
    2027-03
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia
    InterventionOMN6; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections

    NCT07503600 · start 2026-03-26

    Registered record
    Registry ID
    NCT07503600
    Conditions
    Multidrug-Resistant Gram-Negative Bacterial Infections; Antimicrobial Resistance
    Interventions
    Melatonin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03-26
    Completion
    2026-08-26
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug-Resistant Gram-Negative Bacterial Infections; Antimicrobial Resistance
    InterventionMelatonin; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety.

    NCT07694700 · start 2025-12-30

    Registered record
    Registry ID
    NCT07694700
    Conditions
    MDR Bacteria
    Interventions
    Colistimethate sodium for injection, meropenem; Amikacin Injection and meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2025-12-30
    Completion
    2026-09-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDR Bacteria
    InterventionColistimethate sodium for injection, meropenem; Amikacin Injection and meropenem
    PhasePhase 4
    Registry statusActive not recruiting

  • Inhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury

    NCT06819462 · start 2025-04-27

    Registered record
    Registry ID
    NCT06819462
    Conditions
    Ventilator-Associated Pneumonia (VAP); Inha' le' d
    Interventions
    Inhaled colistin; Inhaled 0.9% sodium chloride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-27
    Completion
    2027-06-30
    Enrolment
    444

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator-Associated Pneumonia (VAP); Inha' le' d
    InterventionInhaled colistin; Inhaled 0.9% sodium chloride
    PhaseNot applicable
    Registry statusRecruiting

  • Optimising TREATment for Severe Gram-Negative Bacterial Infections

    NCT07004049 · start 2025-04-21

    Registered record
    Registry ID
    NCT07004049
    Conditions
    Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection; Multidrug Resistance
    Interventions
    Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline; Colistin/Polymyxin B + Meropenem; Ceftazidime-avibactam + Sulbactam; Ceftazidime-avibactam + Fosfomycin; Ceftazidime-avibactam; Ceftazidime-avibactam + Aztreonam; Ceftazidime-avibactam + Colistin/Polymyxin B; High-dose meropenem; Meropenem + Fosfomycin; Meropenem-vaborbactam; Cefiderocol; Ceftolozane-tazobactam; Ceftolozane-tazobactam + Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-04-21
    Completion
    2028-12-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection +1 more
    InterventionColistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline; Colistin/Polymyxin B + Meropenem; Ceftazidime-avibactam + Sulbactam +10 more
    PhasePhase 4
    Registry statusRecruiting

  • Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

    NCT07089186 · start 2025-04-12

    Registered record
    Registry ID
    NCT07089186
    Conditions
    Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI); Complicated Urinary Tract Infection (cUTI); Bloodstream Infection (BSI)
    Interventions
    Meropenem and Pralurbactam; Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-12
    Completion
    2027-04
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI); Complicated Urinary Tract Infection (cUTI) +1 more
    InterventionMeropenem and Pralurbactam; Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
    PhasePhase 3
    Registry statusRecruiting

  • Therapeutic Options for CRAB

    NCT06440304 · start 2025-01-30

    Registered record
    Registry ID
    NCT06440304
    Conditions
    Infections, Bacterial; Sepsis Bacterial
    Interventions
    Fosfomycin; Eravacycline; ampicillin/sulbactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-01-30
    Completion
    2027-02
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial; Sepsis Bacterial
    InterventionFosfomycin; Eravacycline; ampicillin/sulbactam
    PhasePhase 4
    Registry statusRecruiting

  • Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline

    NCT06893835 · start 2024-12-01

    Registered record
    Registry ID
    NCT06893835
    Conditions
    Infection in ICU
    Interventions
    Colistimethate Sodium; Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-12-01
    Completion
    2025-06-30
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection in ICU
    InterventionColistimethate Sodium; Tigecycline
    PhasePhase 4
    Registry statusActive not recruiting

  • Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity

    NCT06650384 · start 2024-11-01

    Registered record
    Registry ID
    NCT06650384
    Conditions
    Nephrotoxicity
    Interventions
    Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin; Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2024-11-01
    Completion
    2026-02-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNephrotoxicity
    InterventionAddition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin; Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

    NCT05922124 · start 2024-09-01

    Registered record
    Registry ID
    NCT05922124
    Conditions
    Carbapenem Resistant Bacterial Infection; Acinetobacter Bacteremia; Acinetobacter Pneumonia
    Interventions
    Cefiderocol; Ampicillin-sulbactam; Colistin; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-09-01
    Completion
    2026-09
    Enrolment
    734

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem Resistant Bacterial Infection; Acinetobacter Bacteremia; Acinetobacter Pneumonia
    InterventionCefiderocol; Ampicillin-sulbactam; Colistin; Meropenem
    PhasePhase 4
    Registry statusRecruiting

  • Colistin Dosage Prsonalization Approach

    NCT06472271 · start 2024-07-30

    Registered record
    Registry ID
    NCT06472271
    Conditions
    Colistin Adverse Reaction
    Interventions
    Polymyxin e
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-07-30
    Completion
    2025-10-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColistin Adverse Reaction
    InterventionPolymyxin e
    PhaseNot recorded
    Registry statusRecruiting

  • Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

    NCT06051513 · start 2023-11-27

    Registered record
    Registry ID
    NCT06051513
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection
    Interventions
    treatment with or without colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-11-27
    Completion
    2025-12-31
    Enrolment
    404

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection
    Interventiontreatment with or without colistin
    PhaseNot applicable
    Registry statusRecruiting

  • Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital

    NCT05862402 · start 2023-05-07

    Registered record
    Registry ID
    NCT05862402
    Conditions
    Carbapenem Resistant Klebsiella Pneumoniae
    Interventions
    Dose-adjustment by PKPD
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-05-07
    Completion
    2024-06-30
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem Resistant Klebsiella Pneumoniae
    InterventionDose-adjustment by PKPD
    PhasePhase 4
    Registry statusUnknown